Roth MKM analyst Jason Wittes initiated coverage of TriSalus Life Sciences (TLSI) with a Buy rating and $11 price target The company’s TriNav catheter significantly improves drug delivery with pressure enabled drug delivery, which is on its way to becoming the standard of care for delivering therapeutics to tumors in the liver, the analyst tells investors in a research note. The firm says this alone supports 50% growth through 2027, with upside from clinical expansion beyond the liver.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TLSI:
- TriSalus Life Sciences files to sell 10.59M shares of common stock for holders
- TriSalus Life Sciences initiated with an Outperform at Northland
- TriSalus Life Sciences management to meet with Oppenheimer
- TriSalus: PEDD method via TriNav Infusion System aided penetration of GM
- TriSalus Life Sciences initiated with an Outperform at Oppenheimer
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
